SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation
CRSP 52.51+2.7%Nov 14 9:30 AM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: tuck who wrote (7871)2/17/2003 12:01:48 PM
From: Biomaven  Read Replies (1) of 52153
 
Thanks, Tuck - very interesting article. It does show the "terms of trade" between pharma and biotechs have swung more in favor of biotechs, except perhaps for royalty rates for early stage products.

Nigel commented how well Roche shows - I've also been very impressed with their choice of early stage deals. I've also never heard a breath of complaint about their royalty calculations - seems like their drugs division must come from a different planet than their diagnostics and vitamin divisions.

Peter
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News